Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Eli Lilly And Co (LLY) Price & Performance

Invesco DB Commodity Index Tracking FundTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Invesco DB Commodity Index Tracking Fund vs Eli Lilly And Co — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $29.97, while Eli Lilly And Co trades at $1,214.88 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while Invesco DB Commodity Index Tracking Fund pays none. Which is the better fit depends on your goals.

DBCLLY
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$31.69$1.24K
52-Week Low
$21.62$635.22
Market Cap
$1.10T
Enterprise Value
$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Commodity Index Tracking Fund

DBC trades at $28.91, up 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. Financial ratios are unavailable in the provided data. Recent news highlights commodities ETFs as inflation hedges, with articles discussing portfolio strategies and geopolitical impacts on commodity markets.

The outlook for DBC is clouded by bearish technicals and lack of fundamental data. Commodity market volatility from geopolitical tensions offers potential upside, but investors face risks from unclear financial health and market sentiment shifts. Careful evaluation of upcoming earnings and analyst coverage is essential.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco DB Commodity Index Tracking Fund

DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.

Read more on DBC

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY